Bill Text: CA AB1327 | 2019-2020 | Regular Session | Amended
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Medi-Cal: reimbursement rates.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Vetoed) 2020-09-29 - Vetoed by Governor. [AB1327 Detail]
Download: California-2019-AB1327-Amended.html
Bill Title: Medi-Cal: reimbursement rates.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Vetoed) 2020-09-29 - Vetoed by Governor. [AB1327 Detail]
Download: California-2019-AB1327-Amended.html
|
Amended
IN
Assembly
March 27, 2019 |
CALIFORNIA LEGISLATURE—
2019–2020 REGULAR SESSION
| Assembly Bill | No. 1327 |
| Introduced by Assembly Member Petrie-Norris (Coauthor: Assembly Member Arambula) |
February 22, 2019 |
An act to amend Section 11839.2 of the Health and Safety Code, relating to narcotic treatment programs.
LEGISLATIVE COUNSEL'S DIGEST
AB 1327, as amended, Petrie-Norris.
Narcotic treatment programs: safe storage devices.
Existing law requires the State Department of Health Care Services to license narcotic treatment programs to use narcotic replacement therapy in the treatment of addicted persons. Existing law specifies the controlled substances a licensed narcotic treatment program may use for narcotic replacement therapy by licensed narcotic treatment programs, including methadone and buprenorphine products.
This bill would require narcotic treatment programs to provide safe storage products, as defined, to every patient who is eligible to take medication off the premises.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NOBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 11839.2 of the Health and Safety Code is amended to read:11839.2.
(a) The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(1) Methadone.
(2) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.
(3) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.
(4) Any other medication approved by the federal Food and Drug
Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders.
(b) A licensed narcotic treatment program shall provide a safe storage product, as defined in Section 4106.5 of the Business and Professions Code, to every patient who is licensed eligible to take any of the medications listed in subdivision (a) off the premises.
(c) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider
bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
